CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale Director sold 30,000 shares at $70.05 ($2,101,590)
- 4 Open-market sale Director sold 10,000 shares at $60.03 ($600,310)
- 4 Open-market sale Director sold 10,000 shares at $50.18 ($501,830)
- 4 Open-market sale Chief Medical Officer sold 52,906 shares at an average $40.74 ($2,155,603)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Medical Officer sold 3,689 shares at $31.00 ($114,359)
- 4 Shares withheld for taxes Chief Medical Officer gave up 1,954 shares (to pay taxes)
- 4 Shares withheld for taxes COO and Secretary gave up 1,954 shares (to pay taxes)
- 4 Shares withheld for taxes CFO and Treasurer gave up 1,954 shares (to pay taxes)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale 10% owner sold 1,443,247 shares at $31.65 ($45,678,768)
- 4 Open-market sale 10% owner sold 250,000 shares at an average $23.97 ($5,993,052)
- 4 Open-market sale 10% owner sold 255,000 shares at an average $24.72 ($6,304,373)
- 4 Gift President and CEO gave 40,000 shares (gift)
- 4 Open-market sale Director sold 400,000 shares at $26.10 ($10,440,000)
- 4 Open-market sale 10% owner sold 1,922,855 shares at $25.75 ($49,513,516)
- 4 Derivatives Options or other derivatives
Page 15 of 22 · 436 filings